USP10 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4408407	0.50	6/20
SCHEMBL1923603	0.53	5/20
SCHEMBL1923492	0.53	3/20
SCHEMBL1923430	0.52	3/20
SCHEMBL1923980	0.45	3/20
SCHEMBL612486	0.42	3/20
SCHEMBL12619046	0.38	3/20
SCHEMBL2681306	0.77	2/20
SCHEMBL2681396	0.52	2/20
SCHEMBL1454993	0.51	2/20
SCHEMBL1455594	0.49	2/20
SCHEMBL1640552	0.47	2/20
SCHEMBL2680671	0.46	2/20
SCHEMBL2681208	0.46	2/20
SCHEMBL1923836	0.45	2/20
SCHEMBL1924841	0.42	2/20
SCHEMBL5357868	0.41	2/20
SCHEMBL4356024	0.40	2/20
SCHEMBL4356027	0.40	2/20
SCHEMBL614343	0.37	2/20

Clinical trials — most relevant to USP10 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study	PHASE3	COMPLETED
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)	PHASE2	RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer	PHASE1/PHASE2	COMPLETED
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer	PHASE1/PHASE2	COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer	PHASE1	UNKNOWN
Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer	PHASE1	SUSPENDED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
The Danish TURNER Cryopreservation Study	nan	RECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome	nan	COMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
A Natural History Study of Angelman Syndrome	nan	RECRUITING
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis	nan	UNKNOWN
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases	nan	UNKNOWN
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex	nan	COMPLETED
Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study	nan	COMPLETED
Long Term Prediction of MASH-related HCC Risk by Proteomics	nan	NOT_YET_RECRUITING
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)	nan	UNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Inherited Reproductive Disorders	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a USP10 binder may also engage these)

Protein	Name	Similarity
Q3KR59	—	1.000	Q3KR59 →
P52479	—	1.000	P52479 →
Q2NL57	—	1.000	Q2NL57 →
Q6DIJ4	—	1.000	Q6DIJ4 →
A5PJS6	—	1.000	A5PJS6 →
Q7ZXR7	—	0.997	Q7ZXR7 →
Q5ZJN4	—	0.996	Q5ZJN4 →
F1N5V1	—	0.985	F1N5V1 →
Q8BW70	—	0.985	Q8BW70 →
A8HAL1	—	0.984	A8HAL1 →
Q6PAW2	—	0.984	Q6PAW2 →
F1SRY5	—	0.984	F1SRY5 →
Q8K2L8	—	0.984	Q8K2L8 →
Q08DA3	—	0.984	Q08DA3 →
E1C213	—	0.984	E1C213 →
Q8R5K2	—	0.984	Q8R5K2 →
Q8C0R0	—	0.984	Q8C0R0 →
A5PMR2	—	0.984	A5PMR2 →
Q5XJV7	—	0.983	Q5XJV7 →
Q28C33	—	0.983	Q28C33 →
Q8WYQ5	—	0.983	Q8WYQ5 →
Q9EQM6	—	0.983	Q9EQM6 →
Q86XZ4	—	0.982	Q86XZ4 →
Q9H694	—	0.982	Q9H694 →
Q09YG9	—	0.982	Q09YG9 →
B2GUN4	—	0.982	B2GUN4 →
E2RK09	—	0.982	E2RK09 →
Q8TEW8	—	0.982	Q8TEW8 →
O70546	—	0.982	O70546 →
A6QNM7	—	0.982	A6QNM7 →